In the following video, Motley Fool health-care analyst David Williamson discusses Depomed's (NASDAQ:DEPO) major FDA advisory committee embarrassment. The company's menopause drug Sefelsa received a nearly unanimous vote against it, not based on risk vs. reward, but on efficacy. Depomed paid $1 million for the opportunity to be reviewed by the panel. In the video, David tells investors how the company could have made such a miscalculation, why it could be a win on the market if the drug were to be approved, but why it's such a long shot that it isn't worth the risk, and what else Depomed has in its arsenal.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Depomed Executes an Exit Strategy for Its Opioid Drug
The company hopes a restructuring of its business can help it get back on its feet.
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.
Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
These stocks helped drag the market lower. Find out why.